12 results
ARS
2023 FY
TARS
Tarsus Pharmaceuticals Inc
26 Apr 24
Annual report to shareholders
4:27pm
potential of TP-04 as a novel topical gel formulation for the treatment of rosacea, a chronic skin disease characterized by facial redness … Demodex blepharitis by incorporating eyelid screening as part of their routine exams. Blepharitis: Market Overview Blepharitis is a common, chronic
8-K
EX-99.1
TARS
Tarsus Pharmaceuticals Inc
8 Jan 24
Leading the Way in Category Creation J A N U A R Y 2 0 2 4 Sulma, an XDEMVY® Patient
9:00am
papulopustular rosacea (PPR)2 Rosacea Chronic skin disease characterized by facial redness, inflammatory lesions, burning and stinging For Investor
8-K
EX-99.1
TARS
Tarsus Pharmaceuticals Inc
15 Jun 23
Regulation FD Disclosure
4:04pm
Summary: 72-year-old male; redness, swollen lids, painful, self-described as “miserable” Chronic chalazia (~18 months, 2-3 per lid) that needed … and chronic/recurrent “stye” formation OU 27 © Tarsus Pharmaceuticals | For Investor Purposes Only
Case 1: Examination 28 BSCVA: 20/20 OU Exam Findings
ARS
2022 FY
TARS
Tarsus Pharmaceuticals Inc
26 Apr 23
Annual report to shareholders
4:08pm
Rosacea is a chronic skin disease characterized by facial redness, inflammatory lesions, burning and stinging, which can flare up in response to certain … is a common, chronic ophthalmic lid margin disease characterized by inflammation of the eyelid margin, redness and ocular irritation. It is also
10-K
b1bfan
31 Mar 21
Annual report
5:01pm
424B4
y91qzm zp
16 Oct 20
Prospectus supplement with pricing info
4:40pm
S-1/A
1ijk7bodxlkqof h5im
9 Oct 20
IPO registration (amended)
5:16pm
S-1
cqf727g 4f
25 Sep 20
IPO registration
5:25pm
DRS/A
yzyb8poi 8qd
14 Sep 20
Draft registration statement (amended)
12:00am
DRS
g4tvjn
7 Aug 20
Draft registration statement
12:00am
- Prev
- 1
- Next